Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) - Overview
Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) - Companies Involved in Therapeutics Development
Biomics Biotechnologies Co Ltd
Boehringer Ingelheim Intertiol GmbH
Canget BioTekpharma LLC
IMV Inc
MimiVax LLC
Optimum Therapeutics LLC
Oxford Vacmedix UK Ltd
Polyplus-Transfection SA
Stemline Therapeutics Inc
Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) - Drug Profiles
Antibody to Target Survivin for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antisense Ri Oligonucleotide to Inhibit Survivin and Bcl-2 for Bladder Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antisense Ri Oligonucleotide to Inhibit Survivin and Cyclin B1 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antisense Ri Oligonucleotides to Inhibit Survivin for Pancreatic Cancer and Bladder Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BGA-005 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BI-1361849 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BKM-1644 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BKM-1740 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DPX-Survivac - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FL-118 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MV-2C2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MX-106 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OVM-200 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SL-701 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
UC-112 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine for Autoimmune Diseases and Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine for Colon Carcinoma and Lymphoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine for Neuroblastoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target BIRC5 for Relapsed Multiple Myeloma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) - Dormant Products
Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) - Discontinued Products
Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) - Product Development Milestones
Featured News & Press Releases
Jun 12, 2019: New Phase 2 clinical trial results continue to demonstrate potential clinical benefit of IMV’s DPX-survivac in combition with Merck’s Keytruda in patients with DLBCL
Jun 04, 2019: IMV to provide update on phase 2 clinical results with Merck Keytruda in DLBCL by means of conference Call and Webcast
Jun 01, 2019: Phase II trial shows favorable response for patients receiving combition therapy with SurVaxM
Jun 01, 2019: Imv presents new positive data from phase 2 monotherapy arm of its decide1 trial in advanced ovarian cancer and continued duration of clinical benefits to patients with progression free survival
May 16, 2019: IMV to present new data at 2019 ASCO annual meeting from its Phase 2 clinical trial evaluating DPX-Survivac in Ovarian Cancer
Apr 18, 2019: IMV to provide updated clinical data at 2019 ASCO annual meeting on lead candidate DPX-Survivac in Ovarian Cancer and other solid tumors
Mar 26, 2019: Initial phase 2 data from an IMV clinical study continues to demonstrate DPX-Survivac’s prior trend as a potential monotherapy treatment for advanced ovarian cancer
Jan 29, 2019: IMV announces clinical update for DPX-Survivac program in ovarian cancer following positive feedback from U.S. FDA
Dec 13, 2018: IMV presents updated positive data from phase 1b/2 combition clinical trial in advanced ovarian cancer at 2018 ESMO Immuno-Oncology Congress
Dec 10, 2018: IMV Announces Updated Clinical Data Presentation for Lead Candidate DPX-Survivac’s Phase 1b/2 Immunotherapy Combition Trial at the ESMO Immuno-Oncology Congress 2018
Nov 28, 2018: Brain Cancer Immunotherapy SurVaxM extends survival, even in hard-to-treat patients
Nov 22, 2018: IMV amends Phase Ib/II trial of recurrent ovarian cancer drug
Nov 16, 2018: Stemline Therapeutics announces oral presentation of SL-701 phase 2 data in second-line Glioblastoma at the 23rd Annual Meeting of the Society of Neuro-Oncology (SNO)
Oct 16, 2018: Stemline Therapeutics announces SL-701 clinical data to be featured, including an Oral Presentation, at upcoming ESMO 2018 Congress
Sep 18, 2018: IMV announces early positive results from phase 2 clinical trial of lead candidate DPX-Survivac in combition with Merck’s Keytruda in patients with DLBCL
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019


List of Tables


Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Biomics Biotechnologies Co Ltd, H2 2019
Pipeline by Boehringer Ingelheim International GmbH, H2 2019
Pipeline by Canget BioTekpharma LLC, H2 2019
Pipeline by IMV Inc, H2 2019
Pipeline by MimiVax LLC, H2 2019
Pipeline by Optimum Therapeutics LLC, H2 2019
Pipeline by Oxford Vacmedix UK Ltd, H2 2019
Pipeline by Polyplus-Transfection SA, H2 2019
Pipeline by Stemline Therapeutics Inc, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Dormant Products, H2 2019 (Contd..2), H2 2019
Discontinued Products, H2 2019